Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC8VNH)

Drug Name
Flufenamic Acid Drug Info
Synonyms
flufenamic acid; 530-78-9; Fluphenamic acid; Nichisedan; Achless; Arlef; Tecramine; Paraflu; Lanceat; Flufacid; Plostene; Fullsafe; Parlef; Surika; Parlif; Flufenaminsaeure; Reumajust A; Acido flufenamico; N-(3-Trifluoromethylphenyl)anthranilic acid; Ristogen; Sastridex; Meralen; Ansatin; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; Fluore-200; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; ANT-1; Acide flufenamique; Acidum flufenamicum; TVX 916; INF 1837; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; NSC-82699; CI 440
Indication
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [1]
Cross-matching ID
PubChem CID
3371
ChEBI ID
CHEBI:42638
CAS Number
CAS 530-78-9
TTD Drug ID
DMC8VNH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [9]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [10]
Darolutamide DMV7YFT Prostate cancer 2C82.0 Approved [11]
Testosterone DM7HUNW Hot flushes GA30 Approved [12]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [13]
Fludrocortisone DMUDIR8 Addison disease 5A74.0 Approved [14]
ARN-509 DMT81LZ Acute myeloid leukaemia 2A60 Approved [15]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [16]
Nandrolone DMFWKG1 Osteoporosis FB83.0 Approved [17]
Fluoxymesterone DMUHCF1 Breast cancer 2C60-2C65 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [19]
Naproxen DMZ5RGV Bursitis Approved [20]
Mesalazine DMOL5IU Diverticulitis Approved [21]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [22]
Bromfenac DMKB79O Pain MG30-MG3Z Approved [23]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [24]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [24]
Suprofen DMKXJZ7 Miosis LA11.62 Approved [25]
Gamma-Homolinolenic acid DMSXKYG Malnutrition 5B50-5B71 Approved [26]
FENBUFEN DMXGDFK Arthritis FA20 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dihydrodiol dehydrogenase type I (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ASP-9521 DM8V0UL Prostate cancer 2C82.0 Phase 1/2 [28]
N-(benzimidazole/indole) benzoic acid derivative 2 DMOPUFM N. A. N. A. Patented [29]
N-(phenylamino)-benzoate derivative 1 DMNIWVG N. A. N. A. Patented [29]
Indomethacin analog 3 DM53JXE N. A. N. A. Patented [29]
Indomethacin analog 2 DMKFPJ7 N. A. N. A. Patented [29]
Beta-naphthylacetic acids derivative 1 DM5KTDY N. A. N. A. Patented [29]
Indomethacin analog 1 DM3E5V6 N. A. N. A. Patented [29]
N-(naphthylamino)-benzoate derivative 1 DM310ES N. A. N. A. Patented [29]
N-(benzimidazolylcarbonyl)-piperidine derivative 1 DM541QW N. A. N. A. Patented [29]
Nitrogen/sulfur-substituted estrene derivative 1 DMD7OW0 N. A. N. A. Patented [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [30]
Naproxen DMZ5RGV Bursitis Approved [20]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [31]
Indomethacin DMSC4A7 Bursitis Approved [24]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [32]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [33]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [34]
Flurbiprofen DMGN4BY Osteoarthritis FA00-FA05 Approved [35]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [22]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [36]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [37]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [38]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [40]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [41]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [42]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [43]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [44]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Peroxisome proliferator-activated receptor gamma (PPARG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [46]
Quercetin DM3NC4M Obesity 5B81 Approved [47]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [48]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [49]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [50]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [51]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [52]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [53]
Stavudine DM6DEK9 Human immunodeficiency virus infection 1C62 Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C4 (AKR1C4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [55]
Diazepam DM08E9O Alcohol withdrawal Approved [56]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
Benzbromarone DMC3YUA Gout FA25 Approved [3]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [58]
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [56]
Flunitrazepam DMGR5Z3 Insomnia 7A00-7A0Z Approved [56]
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [59]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [60]
Indomethacin DMSC4A7 Bursitis Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [61]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [62]
Diazepam DM08E9O Alcohol withdrawal Approved [56]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [63]
Desogestrel DM27U4Y Contraception QA21 Approved [63]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [62]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [62]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [64]
Quercetin DM3NC4M Obesity 5B81 Approved [65]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [62]
Diazepam DM08E9O Alcohol withdrawal Approved [56]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [67]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [68]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [62]
Quercetin DM3NC4M Obesity 5B81 Approved [69]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [70]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [62]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [71]
Testosterone DM7HUNW Hot flushes GA30 Approved [72]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [73]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [62]
Diazepam DM08E9O Alcohol withdrawal Approved [56]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [74]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [62]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [62]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [75]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [76]
Ethacrynic acid DM60QMR Edema MG29 Approved [74]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Low-density lipoprotein receptor (LDLR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [77]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [67]
Desogestrel DM27U4Y Contraception QA21 Approved [77]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [78]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [79]
Quercetin DM3NC4M Obesity 5B81 Approved [69]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [80]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [81]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [82]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [83]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cystic fibrosis transmembrane conductance regulator (CFTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [84]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [85]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [86]
Quercetin DM3NC4M Obesity 5B81 Approved [87]
Miglustat DM5J64S Niemann-Pick disease type C Approved [88]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [89]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [86]
Oxidized glutathione DM9EQC0 Breast cancer 2C60-2C65 Approved [90]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [90]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [91]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By L-selectin (SELL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [6]
Meloxicam DM2AR7L Arthritis FA20 Approved [6]
Methotrexate DM2TEOL Anterior urethra cancer Approved [92]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [93]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [94]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [6]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [95]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [6]
Phenylbutazone DMAYL0T Chronic pain MG30 Approved [6]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Dehydrogenase/reductase SDR family member 11 (DHRS11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [5]
Quercetin DM3NC4M Obesity 5B81 Approved [5]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [96]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [83]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [58]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [97]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [98]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [99]
Suprofen DMKXJZ7 Miosis LA11.62 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Short transient receptor potential channel 6 (TRPC6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Panobinostat DM58WKG Chronic graft versus host disease Approved [100]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [101]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [102]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [100]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [103]
Geldanamycin DMS7TC5 Kidney cancer 2C90.0 Discontinued in Phase 2 [104]
AA-861 DMPEB0Z Allergy 4A80-4A85 Terminated [105]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [106]
Trichostatin A DM9C8NX Solid tumour/cancer 2A00-2F9Z Investigative [104]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Inhibitor [2]
Dihydrodiol dehydrogenase type I (AKR1C3) TT5ZWB6 AK1C3_HUMAN Inhibitor [2]
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [2]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [3]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [3]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [3]
Aldo-keto reductase family 1 member C4 (AKR1C4) OTW2MMOF AK1C4_HUMAN Gene/Protein Processing [3]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [4]
Dehydrogenase/reductase SDR family member 11 (DHRS11) OTU3J0ZL DHR11_HUMAN Gene/Protein Processing [5]
L-selectin (SELL) OT6RAJZR LYAM1_HUMAN Gene/Protein Processing [6]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Gene/Protein Processing [7]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Gene/Protein Processing [8]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Gene/Protein Processing [8]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2447).
2 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
3 Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact. 2003 Feb 1;143-144:503-13.
4 Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol. 2004 Aug;124(2):125-37. doi: 10.1085/jgp.200409059.
5 Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
6 Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem. 2002 Oct 11;277(41):38212-21. doi: 10.1074/jbc.M205142200. Epub 2002 Jul 29.
7 Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. Eur J Pharmacol. 1999 May 21;372(3):311-8. doi: 10.1016/s0014-2999(99)00246-0.
8 Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenaseMediation through different signaling pathways. J Biol Chem. 2000 Sep 8;275(36):28173-9.
9 Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
10 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
12 Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
13 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
14 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
15 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
16 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
17 Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
18 An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
19 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
20 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
21 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
22 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
23 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
24 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
25 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
26 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
27 Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
28 Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
29 Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
30 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
31 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
32 Pfizer. Product Development Pipeline. March 31 2009.
33 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
34 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
35 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
36 Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
37 Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
38 Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
39 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
40 Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
41 Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
42 Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
43 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
44 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
45 A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
46 Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
47 The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
48 Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
49 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
50 Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
51 Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
52 Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
53 Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
54 Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
55 Initro CAPE inhibitory activity towards human AKR1C3 and the molecular basis. Chem Biol Interact. 2016 Jun 25;253:60-5.
56 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
57 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
58 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
59 Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
60 Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
61 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
62 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
63 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
64 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
65 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
66 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
67 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
68 A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
69 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
70 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
71 Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
72 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
73 Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
74 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
75 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
76 Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
77 Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue. Contraception. 2007 Oct;76(4):297-305. doi: 10.1016/j.contraception.2007.06.011. Epub 2007 Sep 14.
78 Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. J Biol Chem. 2020 Nov 20;295(47):15870-15882. doi: 10.1074/jbc.RA120.015623. Epub 2020 Sep 10.
79 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
80 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
81 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
82 Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
83 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
84 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
85 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
86 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
87 Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
88 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
89 Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
90 Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
91 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
92 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
93 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
94 The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006 Jan 20;218(1):30-8. doi: 10.1016/j.tox.2005.09.014. Epub 2005 Nov 16.
95 Immunological consequences of thalidomide treatment in Sj?gren's syndrome. Ann Rheum Dis. 2006 Jan;65(1):112-4. doi: 10.1136/ard.2005.038406.
96 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
97 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
98 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
99 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
100 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
101 Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
102 Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
103 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
104 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
105 The role of transient receptor potential channel blockers in human gastric cancer cell viability. Can J Physiol Pharmacol. 2012 Feb;90(2):175-86. doi: 10.1139/y11-114. Epub 2012 Feb 6.
106 Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.